| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-AXL (extracellular) Antibody is an antibody targeting AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IFC, IHC, LCI, WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO (also reported as AXL Receptor Tyrosine Kinase, Tyrosine-Protein Kinase Receptor UFO, AXL Oncogene, Tyro7, UFO).
- Immunogen/epitope region: Extracellular, N-term..
- Homology note: Mouse, Rat - 14 out of 15 amino acids residues identical (informative for cross-species interpretation).
- Species reactivity (as provided): Human, Rat, Mouse.
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
- Conjugate/format: Unconjugated (may affect detection channel and background).
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
AXL, also known as Tyrosine Kinase Receptor UFO and Tyro7, is a member of the receptor tyrosine kinase TAM family, that includes the receptors Tyro3, AXL and MERTK 1,2.The TAM family receptors are widely expressed in normal cells and tissues, such as monocytes, platelets, endothelial cells, brain and heart, where they regulate cell survival, non-inflammatory clearance of apoptotic cells by phagocytic cells, natural killer cell differentiation, platelet aggregation, and more 1,2.The TAM family receptors show structural similarities with other tyrosine kinase receptors, that is, an extracellular N-terminal domain containing two immunoglobulin-like and two fibronectin 3 domains, followed by a hydrophobic single pass transmembrane domain, and a cytoplasmic C-terminal tail containing a tyrosine kinase domain1,2.Axl and the other TAM receptors can be activated via their ligands, growth arrest specific 6 protein (Gas6) and Protein S (Pros1), which are members of the family of vitamin K-dependent proteins 3.Both AXL receptor and its high affinity ligand Gas6, are key regulators of immune cell activation, and have been shown to be expressed in cancer cells where they promote survival and invasion and contribute to resistance to various therapies 3,4,5. AXL expression is linked to increased risk of metastasis and poor survival in a variety of solid cancers including breast cancer, non-small cell lung carcinoma, ovarian cancer, and clear cell renal carcinoma 3,4. AXL activation in cancer cells and various stromal cells also results in tumor microenvironment deregulation, leading to modulation of angiogenesis, fibrosis, immune response and hypoxia 3,4.Based on these findings, AXL has been identified as a critical therapeutic target for solid cancers, and indeed several therapeutic modalities including small molecules and monoclonal antibodies, are currently being developed 2, 4.
Research relevance and current trends
- Comparing target expression across perturbations, genotypes, or treatment conditions.
- Interpreting localization shifts alongside pathway or phenotypic readouts.
- Using orthogonal controls (KO/KD, peptide competition, isotype concepts) to support conclusions.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
- Immunohistochemistry (IHC): examine spatial distribution in tissue and relate signal to cell-type composition.
- Immunofluorescence/ICC: assess subcellular localization and co-localization with markers in cells or sections.
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
- Live cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: BLP-TR032.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-TR032; Negative control: BLP-TR032.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
